Members |
targetComponentId |
Humerus X-ray |
Plain X-ray of humerus (procedure) |
Humerus X-ray |
Plain X-ray of humerus (procedure) |
Humid environment |
Humid environment (finding) |
bivirkning af Humulin insulin |
Adverse reaction caused by human insulin (disorder) |
patients mand |
Husband |
Hyaline membrane disease |
Respiratory distress syndrome in the newborn |
Hyaluronidase 1500unt/10mL injection |
Product containing precisely bovine hyaluronidase 150 unit/1 milliliter conventional release solution for injection (clinical drug) |
hyaluronidase 150 enheder/ml injektionsvæske, opløsning, hætteglas a 10 ml |
Product containing precisely bovine hyaluronidase 150 unit/1 milliliter conventional release solution for injection (clinical drug) |
hyaluronidase 150 enheder/ml injektionsvæske, opløsning, hætteglas a 1 ml |
Product containing precisely bovine hyaluronidase 150 unit/1 milliliter conventional release solution for injection (clinical drug) |
mola hydatidosa |
Hydatidiform mole, benign (morphologic abnormality) |
hydralazinhydrochlorid 20 mg pulver til injektionsvæske, hætteglas |
Hydralazine hydrochloride 20 mg powder for solution for injection vial |
middel mod tuberkulosemiddel baseret på hydrazid |
Antituberculosis agent |
bivirkning af middel mod tuberkulosemiddel baseret på hydrazid |
Isoniazid adverse reaction |
Mekanisk misforhold pga. hydrocephalus, ikke nærmere specificeret |
Hydrocephalic disproportion |
Mekanisk misforhold pga. hydrocephalus, uspecificeret |
Hydrocephalic disproportion |
Mekanisk misforhold pga. hydrocephalus med prænatalt problem |
Hydrocephalic disproportion |
Hydrochlorothiazide + quinapril hydrochloride |
Product containing hydrochlorothiazide and quinapril (medicinal product) |
Hydrochlorothiazide + quinapril hydrochloride 12.5mg/10mg tablet |
Hydrochlorothiazide 12.5 mg and quinapril (as quinapril hydrochloride) 10 mg oral tablet |
Hydrochlorothiazide 25mg |
Hydrochlorothiazide 25 mg oral tablet |
Hydrocortisone 1% + Pramocaine 1% conventional release rectal foam |
Hydrocortisone and pramocaine only product |
hydrocortison 1 % + pramocain 1 % skumklysma |
Hydrocortisone and pramocaine only product |
hydrocortison 100 mg pulver og solvens til injektionsvæske, opløsning, hætteglas |
Hydrocortisone (as hydrocortisone sodium succinate) 100 mg powder for solution for injection vial |
Hydrocortisone 100mg/60mL |
Product containing precisely hydrocortisone 1.67 milligram/1 milliliter conventional release rectal suspension (clinical drug) |
hydrocortison 100 mg/60 ml klysma |
Product containing precisely hydrocortisone 1.67 milligram/1 milliliter conventional release rectal suspension (clinical drug) |
hydrocortison 2 % |
Hydrocortisone acetate 20 mg/mL cutaneous lotion |
hydrocortisonacetat 1 % øjendråber |
Hydrocortisone 10 mg/mL eye solution |
hydrocortisonacetat 2,5 % creme |
Product containing precisely hydrocortisone 25 milligram/1 milliliter conventional release cutaneous cream (clinical drug) |
hydrocortisonacetat 1,5 % + neomycinsulfat 0,5 % øjendråber |
Hydrocortisone acetate 15 mg/mL and neomycin (as neomycin sulfate) 5 mg/mL eye solution |
hydrocortisoncypionat 10 mg/5 ml suspension |
Product containing precisely hydrocortisone 2 milligram/1 milliliter conventional release oral suspension (clinical drug) |
Hydrocortisone/neomycin cream |
Hydrocortisone acetate 10 mg/g and neomycin sulfate 5 mg/g cutaneous cream |
Hydrolyase |
Hydrolyase |
hydromorphonhydrochlorid 100% pulver |
Hydromorphone only product |
hydromorphonhydrochlorid kapsel med modificeret udløsning a 12 mg |
Product containing only hydromorphone in oral dose form (medicinal product form) |
Hydromorphone hydrochloride 12mg prolonged-release oral capsule |
Product containing only hydromorphone in oral dose form (medicinal product form) |
hydromorphonhydrochlorid 1 mg/ml injektionsvæske, opløsning, ampul |
Hydromorphone hydrochloride 1 mg/mL solution for injection |
hydromorphonhydrochlorid kapsel med modificeret udløsning a 32 mg |
Product containing only hydromorphone in oral dose form (medicinal product form) |
Hydromorphone hydrochloride 32mg prolonged-release oral capsule |
Product containing only hydromorphone in oral dose form (medicinal product form) |
hydromorphonhydrochlorid 4 mg/ml injektionsvæske, opløsning, ampul |
Hydromorphone hydrochloride 4 mg/mL solution for injection |
Hydrotherapy NOS |
Hydrotherapy |
Hydrotherapy NOS |
Hydrotherapy |
Hydrous wool fat+zinc oxide 4/8% conventional release cutaneous cream |
Lanolin and zinc oxide only product in cutaneous dose form |
lanolin 4 % + zinkoxid 8 % creme |
Lanolin and zinc oxide only product in cutaneous dose form |
hydroxocobalamin 1 mg/ml injektionsvæske, opløsning, ampul a 1 ml |
Product containing precisely hydroxocobalamin (as hydroxocobalamin acetate) 1 milligram/1 milliliter conventional release solution for injection (clinical drug) |
Hydroxocobalamin 2.5g powder for conventional release solution for injection vial |
Product containing only hydroxocobalamin in parenteral dose form (medicinal product form) |
hydroxocobalamin 2,5 g pulver til injektionsvæske, opløsning, hætteglas + diluent |
Product containing only hydroxocobalamin in parenteral dose form (medicinal product form) |
Hydroxyethylcellulose 0.44% conventional release eye drops |
Product containing only hyetellose (medicinal product) |
hydroxyethylcellulose 0,44 % øjendråber til engangsbrug |
Product containing only hyetellose (medicinal product) |
Hydroxypropyl methylcellulose 0.32% conventional release eye drops |
Hypromellose 3.2 mg/mL eye solution |
hydroxypropylmethylcellulose 0,32 % øjendråber til engangsbrug |
Hypromellose 3.2 mg/mL eye solution |
hydroxypropylmethylcellulose 2 % øjendråber |
Product containing precisely hypromellose 2 milligram/1 milliliter conventional release eye solution (clinical drug) |
Hymenoptera species |
Order Hymenoptera (organism) |
allergi over for hyoscinbutylbromid |
Allergy to hyoscine |
hyoscinhydrobromid 0,125 % øjendråber |
Hyoscine (as hyoscine hydrobromide) 1.25 mg/mL eye solution |
hyoscinhydrobromid 0,25 % øjendråber |
Product containing precisely scopolamine (as scopolamine hydrobromide) 2.5 milligram/1 milliliter conventional release eye solution (clinical drug) |
hyoscinhydrobromid 0,5 % øjendråber |
Hyoscine (as hyoscine hydrobromide) 5 mg/mL eye solution |
allergi over for hyoscinhydrobromid |
Allergy to hyoscine |
hyoscyaminsulfat 0,031 mg/1 ml |
Hyoscyamine only product |
hyoscyaminsulfat 0,125 mg/5 ml eliksir |
Hyoscyamine sulfate 25 microgram/mL oral solution |
Hyoscyamine sulfate 0.125mg/5mL liquid |
Hyoscyamine sulfate 25 microgram/mL oral solution |
Hyoscyamine sulfate 0.125mg/mL liquid |
Hyoscyamine sulfate 25 microgram/mL oral solution |
Hyperalphaglobulinemia |
Hyperalphaglobulinemia |
Hyperbetaglobulinemia |
Hyperbetaglobulinemia |
hyperkalcæmi forårsaget af thiazid OG A-vitamin |
Hypercalcemia caused by thiazide and/or retinol (disorder) |
Hyperchromia |
Hyperchromatism |
Hypercupremia |
Blood copper level above reference range |
for stor kobberkoncentration i blodet |
Blood copper level above reference range |
Hyperglobulinemia |
Hyperglobulinaemia |
Hyperglycemia clinical management plan |
Hyperglycemia clinical management plan |
Hyperglycemia self management plan |
Hyperglycemia self management plan |
hyperhidrose, præmature kaviteter og præmolaraplasi |
A rare autosomal dominant ectodermal dysplasia syndrome characterized by premolar aplasia, hyperhidrosis, and premature graying of the hair. Additional features may include a narrow palate, hypoplastic nails, eyebrow anomalies, a unilateral simian crease, and poorly formed dermatoglyphics. |
Hyperinsulinemia due to benign insulinoma |
Hyperinsulinemia due to malignant insulinoma |
Hyperinsulinæmi forårsaget af insulinom |
Hyperinsulinemia due to malignant insulinoma |
Hyperlipidaemia NOS |
Hyperlipidemia |
Hyperlipidemia NOS |
Hyperlipidemia |
klinisk behandlingsplan for hyperlipidæmi |
Hyperlipidaemia clinical management plan |
Hypermenorrhea |
Menorrhagia (finding) |
Hypermobility |
Musculoskeletal hypermobility |
Hyperpyrexia |
Hyperpyrexia (finding) |
Overfølsomhedsalveolit ved lungeormsinfektion |
Hypersensitivity pneumonitis |
Hypersensitivity skin test NOS |
Hypersensitivity skin testing |
Hypersensitivity skin test NOS |
Hypersensitivity skin testing |
Hypersomnolence caused by substance |
Drug-induced hypersomnia |
klinisk behandlingsplan for hypertension |
Hypertension clinical management plan (record artifact) |
Hypertension of pregnancy NOS |
Pregnancy-induced hypertension |
Hypertension under graviditet, ikke nærmere specificeret |
Pregnancy-induced hypertension |
Hypertensive disease NOS |
Hypertensive disorder, systemic arterial (disorder) |
Hypertensive disease NOS |
Hypertensive disorder, systemic arterial (disorder) |
Hypertensive ischemic ulcer |
Ischemic ulcer of skin due to arterial hypertension (disorder) |
Hypertermi hos nyfødt, uspecificeret |
Hyperthermia in newborn |
hypertont saltvand |
Sodium chloride only product |
Hyperton inertia uteri med prænatalt problem |
Hypertonic uterine inertia |
Hypertrichosis and acromegaloid facial appearance syndrome |
Cantu's syndrome |
Hypertrichosis universalis |
Congenital hypertrichosis |
hypertrofisk kardiomyopati associeret med anden sygdom |
Hypertrophic cardiomyopathy due to disorder |
Hypertrofisk kardiomyopati sekundær til Friedreichs ataxi |
Hypertrophic cardiomyopathy due to Friedreich ataxia |
hypertrofisk kardiomyopati sekundær til hypertyroidisme |
Hypertrophic cardiomyopathy due to hyperthyroidism |
Hypertrofisk kardiomyopati sekundær til neuromuskulær sygdom |
Hypertrophic cardiomyopathy due to neuromuscular disorder |
hyperostose |
External hyperostosis |
hypertrofi af knogle og brusk |
External hyperostosis |
hypertrofi af brusk |
Hypertrophy |
Hypnotic |
Hypnotic agent (substance) |